

# American Society of Hematology Annual Meeting (ASH) 2017

Studies from US Oncology Research, The US Oncology Network  
and McKesson Specialty Health Affiliated Investigators

Georgia World Congress Center, Atlanta, GA December 9-12, 2017

Oral Presentations			
Authors	Title	Session #	Date/Time/Location
Anas Younes, <b>John M. Burke</b> , Catherine S Diefenbach, Silvia Ferrari, Cyrus Kahn, <b>Jeffrey P. Sharman</b> , Monica Tani, Chaitra S. Ujjani, Umberto Vitolo, Sam Yuen, Paul Woodard, Kirsten Mundt, Günter Fingerle-Rowson, Surya Chitra, Gila Sellam, Rodica Morariu-Zamfir, and Michael Gilbertson.	Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab and Bendamustine in Patients with Previously Untreated Follicular Lymphoma: An Interim Analysis	623 Abstract # 481 USOR #15054	Sunday, Dec. 10, 4:30 PM Bldg C, Lvl 1, Hall C1
Brad S. Kahl, <b>John M. Burke</b> , Richard van der Jagt, Julie Chang, Peter Wood, Tim Hawkins, David MacDonald, Judith Trotman, David Simpson, <b>Kathryn S. Kolibaba</b> , Samar Issa, Doreen Hallman, Ling Chen, and Ian W. Flinn.	Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial	623 Abstract #484 USOR #07152	Sunday, Dec. 10, 5:15 PM Bldg C, Lvl 1, Hall C1
<b>Jeffrey P. Sharman, Habte Yimer, Michael Boxer, Nicholas Di Bella</b> , Sunil Babu, Jia Li, Yong Mun, Peter Trask, Anthony Mасаquel, Carolina M Reyes, and Alexey Danilov.	Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine	904 Abstract #683 USOR #13177	Monday, Dec. 11, 11:30 AM Bldg C, Lvl 2, C208-C210
<b>Jeffrey P. Sharman, Kathryn S. Kolibaba</b> , Jose Azar, <b>Rama Balaraman, Roger M. Lyons</b> , Mitchell R. Smith, Esteban Abella-Dominicis, Wei Ye, Wen Shi, <b>Thomas Giever</b> , and Andres Forero-Torres.	Evaluating the Efficacy, Safety, and Dose Dependent Activities of Entospletinib in Patients with Chronic Lymphocytic Leukemia	642 Abstract #832 USOR #12154	Monday, Dec. 11, 5:15 PM Bldg B, Lvl 5, Murphy BR 3-4

**Bolded text:** US Oncology Research affiliated investigator

Poster Presentations			
Authors	Title	Session #	Date/Time/Location
<b>Kathryn S. Kolibaba</b> , Mikhail Shtivelband, <b>Edwin C. Kingsley</b> , Mehdi M. Moezi, <b>Donald Richards</b> , <b>Jeffrey P. Sharman</b> , Feng Xiaoshu, Megan Cannan, Rafik Fellague-Chebra, and <b>Roger M. Lyons</b> .	Efficacy and Safety of Ofatumumab and Bendamustine Followed By Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma after Prior Rituximab	623 Abstract #1500 USOR #10255	Saturday, Dec. 9, 5:30 PM to 7:30 PM Bldg A, Lvl 1, Hall A2
<b>Habte Yimer</b> , <b>Jason Melear</b> , <b>Edward Faber</b> , William I. Bensinger, <b>John M Burke</b> , Sriya Gunawardena, Murphy Sean, Hollee Parros, Yana Lutska, Mohamed Darif, Anil Londhe, Ming Qi, Jon Ukropec, Thomas Lin, and <b>Robert M. Rifkin</b> .	Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBORd) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM)	653 Abstract #1839 USOR #16084	Saturday, Dec. 9, 5:30 PM to 7:30 PM Bldg A, Lvl 1, Hall A2
Howard R. Terebello, Rafat Abonour, Cristina J. Gasparetto, Kathleen Toomey, Brian G. M. Durie, James W. Hardin, PhD, Sundar Jagannath, Lynne Wagner, <b>Mohit Narang</b> , Shankar Srinivasan, Lihua Yue, Faiza Zafar, Amani Kitali, Amit Agarwal, and <b>Robert M Rifkin</b> .	Development of a Prognostic Model That Predicts 3- and 5-Year Overall Survival in Multiple Myeloma Using the Connect® MM Patient Registry	653 Abstract #1842 USOR #09141	Saturday, Dec. 9, 5:30 PM to 7:30 PM Bldg A, Lvl 1, Hall A2
Cristina J. Gasparetto, Rafat Abonour, Sundar Jagannath, Brian G. M. Durie, <b>Mohit Narang</b> , Howard R. Terebello, Kathleen Toomey, James W. Hardin, Lynne Wagner, Shankar Srinivasan, Amani Kitali, E. Dawn Flick, Faiza Zafar, Amit Agarwal, and <b>Robert M Rifkin</b> .	Differential Effect of t(11;14) Abnormality on Survival and Depth of Response in African American (AA) and Non-AA (NAA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Connect® MM Registry	653 Abstract #3101 USOR #09141	Sunday, Dec. 10, 6 PM to 8 PM Bldg A, Lvl 1, Hall A2
Sundar Jagannath, <b>Robert M. Rifkin</b> , Cristina J. Gasparetto, Kathleen Toomey, Brian G. M. Durie, James W. Hardin, Howard R. Terebello, Lynne Wagner, <b>Mohit Narang</b> , Shankar Srinivasan, Ahmed YoussefAgha, Amani Kitali, Gail Larkins, Amit Agarwal, and Rafat Abonour.	Development of a Predictive Model of Multiple Myeloma (MM) Patient (pt) Outcomes Based on Treatment Class Transitions Using the Connect® MM patient Registry	653 Abstract #3122 USOR #09141	Sunday, Dec. 10, 6 PM to 8 PM Bldg A, Lvl 1, Hall A2
<b>Mohit Narang</b> , Rafat Abonour, Brian G. M. Durie, Cristina J. Gasparetto, Kathleen Toomey, James W. Hardin, Sundar Jagannath, Howard R. Terebello, Lynne Wagner, Shankar Srinivasan, E. Dawn Flick, Faiza Zafar, Amani Kitali, Amit Agarwal, and <b>Robert M Rifkin</b> .	Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)	653 Abstract #3156 USOR #09141	Sunday, Dec. 10, 6 PM to 8 PM Bldg A, Lvl 1, Hall A2
Andres Forero-Torres, <b>Kathryn S. Kolibaba</b> , Herve Tilly, Gilles Salles, Lijia Wang, Calvin Lee, and <b>Jeffrey P. Sharman</b> .	Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study	626 Abstract #4120 USOR #13143	Monday, Dec. 11, 6 PM to 8 PM Bldg A, Lvl 1, Hall A2
Alex F. Herrera, Manish R Patel, <b>John M. Burke</b> , Ranjana H. Advani, Bruce D. Cheson, <b>Jeffrey P. Sharman</b> , Elicia Penuel, Andrew G. Polson, Ning Leng, Chunze Li, Eva Schuth, Anjali Vaze, Divya Samineni, Rebecca Elstrom, and Catherine S Diefenbach.	A Phase I Study of the Anti-CD79b THIOMAB™-Drug Conjugate DCDS0780A in Patients (Pts) with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)	626 Abstract #4129 USOR #15053	Monday, Dec. 11, 6 PM to 8 PM Bldg A, Lvl 1, Hall A2

**Bolded text:** US Oncology Research affiliated investigator

Poster Presentations			
Authors	Title	Session #	Date/Time/Location
Jacob D. Soumerai, Ai Ni, Mohamed Darif, Anil Londhe, Guan Xing, Julie Huang, Ming Lin, John C. Byrd, Asher A. Chanan-Khan, Richard R. Furman, Michael Hallek, Peter Hillmen, Jeffrey Jones, <b>Jeffrey P. Sharman</b> , Lucille Ferrante, Vijay Reddy, Lyndah K. Dreiling, Henry Adewoye, Ronald Dubowy, Angela Howes, Danelle F. James, and Andrew D. Zelenetz.	A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia Applicable to Patients Treated with Novel Therapies and Standard of Care	641 Abstract #4303 USOR #11235 #12017	Monday, Dec. 11, 6 PM to 8 PM Bldg A, Lvl 1, Hall A2
Matthew S. Davids, Ian W. Flinn, Anthony R. Mato, Owen A. O'Connor, Danielle M. Brander, Matthew A. Lunning, Julie M. Vose, Loretta Nastoupil, Nathan Fowler, Christopher Flowers, Jennifer R. Brown, Marshall T. Schreeder, Nilanjan Ghosh, Frederick Lansigan, Bruce D. Cheson, Paul M. Barr, John M. Pagel, Alexey Danilov, Javier Pinilla Ibarz, Changchun Deng, <b>John M. Burke</b> , Tanya Siddiqi, Manish R Patel, Charles M. Farber, Parameswaran Venugopal, John G. Gribben, Pier Luigi Zinzani, Hari P Miskin, Peter Sportelli, Michael S. Weiss, and Susan M. O'Brien.	An Integrated Safety Analysis of the Next Generation PI3K $\delta$ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies	623 Abstract #4037 USOR #15229 #16065	Monday, Dec. 11, 6 PM to 8 PM Bldg A, Lvl 1, Hall A2

Poster Presentations (HEOR)			
Authors	Title	Session #	Date/Time/Location
<b>Robert M Rifkin, E Susan Amirian</b> , Rohan Medhekar, <b>Thomas Wilson, Marley Boyd</b> , Khalid Mezzi, and Sumeet Panjabi.	Carfilzomib Dosing Patterns and Time to Next Treatment Among Adult Patients with Multiple Myeloma Treated in the US Community Oncology Setting	904 Abstract #3433 HEOR	Sunday, Dec. 10, 6 PM to 8 PM Bldg A, Lvl 1, Hall A2
<b>Robert M Rifkin, E Susan Amirian</b> , Rohan Medhekar, <b>Thomas Wilson, Marley Boyd</b> , Khalid Mezzi, and Sumeet Panjabi.	A Real-World Comparative Analysis of Carfilzomib and Other Systemic Multiple Myeloma Chemotherapies in the US Community Oncology Setting	904 Abstract #3434 HEOR	Sunday, Dec. 10, 6 PM to 8 PM Bldg A, Lvl 1, Hall A2
<b>Jeffrey P. Sharman, Jenny L Black-Shinn, Jamyia Clark</b> , and Bojena Bitman.	Understanding Ibrutinib Treatment Discontinuation Patterns for Chronic Lymphocytic Leukemia	623 Abstract #4060 HEOR	Monday, Dec. 11, 6 PM to 8 PM Bldg A, Lvl 1, Hall A2
Sudeep Karve, <b>Jenny L Black-Shinn, Jamyia Clark, Jeffrey P. Sharman.</b>	MCL Treatment Patterns and Outcomes: A Community Oncology Practice Experience	902 Abstract #4684 HEOR	Monday, Dec. 11, 6 PM to 8 PM Bldg A, Lvl 1, Hall A2

ePub (HEOR)	
Authors	Title
<b>Christopher A. Yasenchak</b> , Joseph Feliciano, <b>Kathleen M. Aguilar, Jamyia Clark, E. Susan Amirian</b> , Akshara Richhariya, et al.	Clinical Profiles, Treatment Characteristics and Outcomes among Newly Diagnosed Hodgkin lymphoma Patients Presenting with Unfavorable and Advanced Disease within a US Community Oncology Setting

**Bolded text:** US Oncology Research affiliated investigator

***Learn More:***

**Online:** [usoncology.com/research](http://usoncology.com/research)

**Email:** [researchopportunities@mckesson.com](mailto:researchopportunities@mckesson.com)

**Phone:** (281) 863-1000

---